ScRPL9A+429-R TTCGTCCTTAACGTTGGTGG oLC4331
ScRPP0+388-F CAGGTAAGACTTCTTTCTTC oLC4332
ScRPP0+576-R GTCGTAAACTTGAACAACAG
CAI4
In vivo selection Rhodamine-6G (µg/ml)
Cycloheximide (µg/ml)
Fluconazole (µg/ml) Beauvericin resistant mutants in the yor1Δ background show increased susceptibility to Pdr5 substrates. Beauvericin-resistant strains with PDR5 mutations (indicated by an R) exhibit sensitivity towards (a) fluconazole, (b) cycloheximide, and (c) rhodamine-6G. The majority of mutants have increased susceptibility to the substrates comparable to the pdr5Δ mutant, and there is no additional effect of beauvericin on susceptibility of these strains. In contrast, beauvericin enhances susceptibility of the wild-type and yor1Δ strains to all Pdr5 substrates tested. MIC assays performed as described in Figure  2a with two-fold serial dilutions of each compound with and without 1 µg/ml of beauvericin in the medium. MIC assays performed in biological triplicates with technical duplicates.
Rhoadamine-6G accumulation Supplementary Figure 4 . Beauvericin-resistant mutants in the yor1Δ background show increased rhodamine-6G accumulation similar to the pdr5Δ mutant. Wild-type S. cerevisiae (BY4741) and yor1Δ strain show minimal rhodamine-6G (1 µg/ml) accumulation unlike pdr5Δ and resistant mutants yor1Δ R1, R2, and R5. Scale bar represents 10 µM. Assay performed in biological duplicates. 
Beauvericin (µg/ml) Supplementary Figure 6 . Deletion of genes encoding CK2 catalytic subunits in the ABC16 strain confers partial resistance to beauvericin. The ABC16 ckb1Δ and ABC16 ckb2Δ strains are robustly resistant to beauvericin, unlike the ABC16 cka1Δ and ABC16 cka2Δ strains. Susceptibility assays performed as described in Figure 2a . MIC assays performed in biological triplicates with technical duplicates. Figure 9 . Antagonism between beauvericin and rapamycin is due to effects on TOR. The antagonism is abrogated in strains lacking FKBP12, but is maintained in a strain lacking PDR5. S. cerevisiae FPR1 and C. albicans RBP1 encode FKBPs that are required for rapamycin-mediated inhibition of TOR. The top panel highlights the antagonism between beauvericin and rapamycin against wild-type strains of S. cerevisiae (BY4741) and C. albicans (BWP17), which is abrogated in the fpr1Δ and rbp1Δ/rbp1Δ strains (middle panel). The antagonism between beauvericin and rapamycin is maintained in a pdr5Δ mutant (bottom panel). Checkerboard assays performed as described in Figure 1b with 24 hours incubation. Checkerboard assays performed in biological triplicates with technical duplicates. 
